Actuate Therapeutics (ACTU) vs BeyondSpring (BYSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BeyondSpring (BYSI) has outperformed Actuate Therapeutics (ACTU) over the past year, losing 82.8% versus a loss of 96.4%. BeyondSpring is the larger company by market cap ($13.7 million vs $13.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACTU | BYSI |
|---|---|---|
| Share price | $0.2253 | $0.33 |
| Market cap | $13.60M | $13.66M |
| 1-day change | +5.38% | -24.49% |
| YTD return | -96.32% | -79.75% |
| 1-year return | -96.43% | -82.77% |
| 5-year return | — | -97.70% |
| EPS (TTM) | $-0.76 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-22.23M | $-1.01M |
| 52-week high | $7.90 | $2.44 |
| 52-week low | $0.174 | $0.299 |
| Distance from 52-week high | -97.15% | -86.48% |
| Analyst consensus | none | — |
| Avg. price target upside | +5084.20% | — |
| Average volume | 807.24K | 261.79K |
| Shares outstanding | 60.38M | 41.41M |
| Employees | 12 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BYSI has outperformed ACTU by 13.7 percentage points over the past year.
About Actuate Therapeutics
ACTU stock →Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About BeyondSpring
BYSI stock →BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
ACTU vs BYSI FAQ
Which is bigger, Actuate Therapeutics or BeyondSpring?
BeyondSpring (BYSI) is larger, with a market capitalization of $13.66M compared with $13.60M for Actuate Therapeutics (ACTU).
Which stock has performed better over the past year, ACTU or BYSI?
BYSI returned -82.77% over the past 12 months, compared with -96.43% for ACTU (price return, excluding dividends). Past performance does not predict future results.
Are Actuate Therapeutics and BeyondSpring in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.